Article
Medicine, General & Internal
Paul Mozarowski, Bhubendra Rasaiah, Melissa Reed, Alexis Lewis, Natalie Walde, Ioannis A. Voutsadakis
Summary: Tumor budding is common in breast cancer patients receiving neo-adjuvant therapy, but it was not found to be associated with tumor characteristics or pathological responses to treatment in this study. Further investigation is needed to determine the potential prognostic value of tumor budding in specific subgroups of breast cancer patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Corrado Tinterri, Andrea Sagona, Erika Barbieri, Simone Di Maria Grimaldi, Giulia Caraceni, Giacomo Ambrogi, Flavia Jacobs, Ersilia Biondi, Lorenzo Scardina, Damiano Gentile
Summary: The controversy over the de-escalation of axillary surgery in breast cancer patients undergoing neo-adjuvant chemotherapy still exists. However, recent studies have shown that a minimally invasive surgical approach of the axilla is safe in patients who become clinically node-negative after neo-adjuvant chemotherapy. This retrospective study aims to assess the reliability of this approach by comparing the characteristics and oncological outcomes of different types of axillary surgery.
Article
Medicine, General & Internal
Sung Ui Jung, Minjung Jung, Jin Hyuk Choi, Chang Wan Jeon
Summary: The case study discussed a female patient with breast cancer who underwent neo-adjuvant systemic therapy with a combination of drugs. The patient received different treatments before and after surgery, ultimately achieving a good therapeutic outcome, providing new insights into the treatment of this type of breast cancer.
Article
Oncology
A. J. Eustace, S. F. Madden, J. Fay, D. M. Collins, E. W. Kay, K. M. Sheehan, S. Furney, B. Moran, A. Fagan, P. G. Morris, A. Teiserskiene, A. D. Hill, L. Grogan, J. M. Walshe, O. Breathnach, C. Power, D. Duke, K. Egan, W. M. Gallagher, N. O'Donovan, J. Crown, S. Toomey, B. T. Hennessy
Summary: The study found that patients with high levels of lymphocyte counts before treatment were more likely to achieve a complete pathological response after chemotherapy. For patients who achieved a pCR after chemotherapy, their immune response may return to baseline after only one cycle of treatment. In patients who did not achieve a pCR, neoadjuvant treatment may stimulate lymphocyte influx into the tumor.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Obstetrics & Gynecology
Jenneke C. Kasius, Jacobus van Der Velden, Nerissa P. Denswil, Jacqueline M. Tromp, Constantijne H. Mom
Summary: The review shows that patients with cervical cancer >2 cm who received neo-adjuvant chemotherapy followed by fertility-sparing surgery had overall favorable characteristics, with approximately 83% successfully undergoing fertility-sparing treatment, about one-third conceiving, and one-fourth having a healthy live-born child.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
(2021)
Article
Oncology
Stefan A. J. Buck, C. Louwrens Braal, Maaike M. Hofman, Esther Oomen-de Hoop, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Koen G. A. M. Hussaarts, Mijntje B. Vastbinder, Quirine C. Van Rossum-Schornagel, Ron H. N. van Schaik, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen
Summary: Combining probenecid with tamoxifen can effectively increase the concentration of endoxifen in breast cancer patients, providing a solution for patients who have poor metabolism or low endoxifen concentrations despite earlier tamoxifen treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Ines Gomez-Acebo, Trinidad Dierssen-Sotos, Monica Mirones, Beatriz Perez-Gomez, Marcela Guevara, Pilar Amiano, Maria Sala, Antonio J. Molina, Jessica Alonso-Molero, Victor Moreno, Claudia Suarez-Calleja, Ana Molina-Barcelo, Juan Alguacil, Rafael Marcos-Gragera, Maria Fernandez-Ortiz, Oscar Sanz-Guadarrama, Gemma Castano-Vinyals, Leire Gil-Majuelo, Conchi Moreno-Iribas, Nuria Aragones, Manolis Kogevinas, Marina Pollan, Javier Llorca
Summary: The study aimed to identify the clinical factors associated with the implementation of the St Gallen-2013 recommendations. Patients who received treatment beyond the recommendations were more likely to have stage II tumors, while those who received less treatment than recommended tended to be older with more severe cancers.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Christine De Bruyn, Jolien Ceusters, Chiara Landolfo, Thais Baert, Gitte Thirion, Sandra Claes, Ann Vankerckhoven, Roxanne Wouters, Dominique Schols, Dirk Timmerman, Ignace Vergote, An Coosemans
Summary: This study found that carboplatin-paclitaxel chemotherapy can reduce immunosuppression and promote immunostimulation in ovarian cancer patients, making the immune system more favorable for the patients. It suggests that chemotherapy induces a temporary window of opportunity for immunotherapy in the treatment of ovarian cancer, by understanding the immune changes that are induced by chemotherapy and surgery.
Article
Oncology
J. M. N. Lopes Cardozo, D. Byng, C. A. Drukker, M. K. Schmidt, M. A. Binuya, L. J. van 't Veer, F. Cardoso, M. Piccart, C. H. Smorenburg, C. Poncet, E. J. T. Rutgers
Summary: In patients with stage I low-risk breast cancer, adjuvant endocrine therapy has a limited effect on distant metastasis-free interval (DMA), but significantly reduces breast cancer events.
ANNALS OF ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Sudpreeda Chainitikun, Sadia Saleem, Bora Lim, Vicente Valero, Naoto T. Ueno
Summary: The review focuses on the development of systemic treatment of IBC from the past to the present, including chemotherapy and targeted therapies. The effects on pathologic complete response (pCR), survival outcomes, predictive markers, and adverse events of these therapies are discussed, along with current standard treatment stratified by molecular subtypes. The future trend of systemic therapy, including immunotherapy and ongoing IBC clinical trials, is also addressed.
JOURNAL OF ADVANCED RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Oana Baldasici, Loredana Balacescu, Daniel Cruceriu, Andrei Roman, Carmen Lisencu, Bogdan Fetica, Simona Visan, Andrei Cismaru, Ancuta Jurj, Lucian Barbu-Tudoran, Valentina Pileczki, Laurian Vlase, Oana Tudoran, Ovidiu Balacescu
Summary: miRNAs expression in plasma sEVs showed no correlation with tissue samples, but can predict pathological response of BC to NAT.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Medicine, General & Internal
Kazuki Nozawa, Akiyo Yoshimura, Hiroji Iwata
Summary: The OlympiA trial showed that adjuvant olaparib significantly improved invasive and distant disease-free survival rates for early breast cancer patients with BRCA1 or BRCA2 mutations. It also reduced recurrence of local lesions and lowered the risk of contralateral breast cancer and second primary ovarian cancer through prophylactic surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Nourhan M. Essa, Heba F. Salem, Marwa O. Elgendy, A. Gabr, Mervat M. Omran, Nivin A. Hassan, Hanaa M. Tashkandi, Steve Harakeh, Marian S. Boshra
Summary: In this study, the researchers found no significant survival benefit in terms of RR and PFS in metastatic breast cancer patients undergoing chemotherapy with the addition of metformin.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Jingyu Ge, Wenjia Zuo, Yiyu Chen, Zhiming Shao, Keda Yu
Summary: Triple-negative breast cancer is highly aggressive and often treated with chemotherapy, which can lead to increased toxicity. Dose-dense chemotherapy may enhance treatment efficacy, and different molecular subtypes may offer potential targets for more personalized treatment strategies.
CANCER BIOLOGY & MEDICINE
(2022)
Review
Oncology
Zhenkun Fu, Zhoujun Lin, Mao Yang, Chenggang Li
Summary: Breast cancer is a common type of cancer, with surgery being the preferred treatment method. Various adjuvant therapies such as radiotherapy, chemotherapy, endocrine therapy, and targeted drug therapy can also be used.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pathology
Eun Young Kang, Joshua Millstein, Gordana Popovic, Nicola S. Meagher, Adelyn Bolithon, Aline Talhouk, Derek S. Chiu, Michael S. Anglesio, Betty Leung, Katrina Tang, Neil Lambie, Marina Pavanello, Annalyn Da-Anoy, Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Christiani Bisinotto, Jesus Garcia-Donas, Sergio Ruiz-Llorente, Monica Yague-Fernandez, Robert P. Edwards, Esther Elishaev, Alexander Olawaiye, Sarah Taylor, Beyhan Ataseven, Andreas du Bois, Philipp Harter, Jenny Lester, Claus K. Hogdall, Sebastian M. Armasu, Yajue Huang, Robert A. Vierkant, Chen Wang, Stacey J. Winham, Sabine Heublein, Felix K. F. Kommoss, Daniel W. Cramer, Naoko Sasamoto, Lilian Van-Wagensveld, Maria Lycke, Constantina Mateoiu, Janine Joseph, Malcolm C. Pike, Kunle Odunsi, Chiu-Chen Tseng, Celeste L. Pearce, Sanela Bilic, Thomas P. Conrads, Arndt Hartmann, Alexander Hein, Michael E. Jones, Yee Leung, Matthias W. Beckmann, Matthias Ruebner, Minouk J. Schoemaker, Kathryn L. Terry, Mona A. El-Bahrawy, Penny Coulson, John L. Etter, Katherine LaVigne-Mager, Juergen Andress, Marcel Grube, Anna Fischer, Nina Neudeck, Greg Robertson, Rhonda Farrell, Ellen Barlow, Carmel Quinn, Anusha Hettiaratchi, Yovanni Casablanca, Ramona Erber, Colin J. R. Stewart, Adeline Tan, Yu Yu, Jessica Boros, Alison H. Brand, Paul R. Harnett, Catherine J. Kennedy, Nikilyn Nevins, Terry Morgan, Peter A. Fasching, Ignace Vergote, Anthony J. Swerdlow, Francisco J. Candido Dos Reis, G. Larry Maxwell, Susan L. Neuhausen, Arantzazu Barquin-Garcia, Francesmary Modugno, Kirsten B. Moysich, Philip J. Crowe, Akira Hirasawa, Florian Heitz, Beth Y. Karlan, Ellen L. Goode, Peter Sinn, Hugo M. Horlings, Estrid Hogdall, Karin Sundfeldt, Stefan Kommoss, Annette Staebler, Anna H. Wu, Paul A. Cohen, Anna DeFazio, Cheng-Han Lee, Helen Steed, Nhu D. Le, Simon A. Gayther, Kate Lawrenson, Paul D. P. Pharoah, Gottfried Konecny, Linda S. Cook, Susan J. Ramus, Linda E. Kelemen, Martin Kobel
Summary: MCM3 mRNA and protein expression levels are associated with survival in patients with tubo-ovarian high-grade serous carcinomas (HGSC), showing a correlation between high MCM3 expression and longer overall survival.
Review
Oncology
Marc Thill, Diana Lueftner, Cornelia Kolberg-Liedtke, Ute-Susann Albert, Maggie Banys-Paluchowski, Ingo Bauerfeind, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Eva Maria Fallenberg, Peter A. Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Joerg Heil, Jens Huober, Christian Jackisch, Hans-Heinrich Kreipe, David Krug, Thorsten Kuehn, Sherko Kuemmel, Sibylle Loibl, Michael Lux, Nicolai Maass, Christoph Mundhenke, Ulrike Nitz, Tjoung-Won Park-Simon, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schuetz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Isabell Witzel, Achim Woeckel, Volkmar Mueller, Wolfgang Janni, Nina Ditsch
Summary: The Breast Committee of the Arbeitsgemeinschaft Gynakologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
Article
Oncology
Ashley Weir, Eun-Young Kang, Nicola S. Meagher, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S. Anglesio, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H. Brand, James D. Brenton, Angela Brooks-Wilson, Michael E. Carney, Julie M. Cunningham, Kara L. Cushing-Haugen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Sian Fereday, Anna Fischer, Luis Paz-Ares, Javier Gayarre, Blake C. Gilks, Marcel Grube, Paul R. Harnett, Holly R. Harris, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y. Hernandez, Sabine Heublein, Yajue Huang, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Felix K. F. Kommoss, Jennifer M. Koziak, Bernhard Kraemer, Nhu D. Le, Jaime Lesnock, Jenny Lester, Jan Lubinski, Janusz Menkiszak, Britta Ney, Alexander Olawaiye, Sandra Orsulic, Ana Osorio, Luis Robles-Diaz, Matthias Ruebner, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Helen Steed, Aline Talhouk, Sarah E. Taylor, Nadia Traficante, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Javier Benitez, Andrew Berchuck, David D. Bowtell, Francisco J. Candido dos Reis, Linda S. Cook, Anna DeFazio, Jennifer A. Doherty, Peter A. Fasching, Maria J. Garcia, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, David G. Huntsman, Beth Y. Karlan, Stefan Kommoss, Francesmary Modugno, Joellen M. Schildkraut, Hans-Peter Sinn, Annette Staebler, Linda E. Kelemen, Caroline E. Ford, Usha Menon, Paul D. P. Pharoah, Martin Koebel, Susan J. Ramus, D. Bowtell, A. DeFazio, N. Traficante, S. Fereday, A. Brand, P. Harnett, R. Sharma
Summary: Recently, a study found a positive correlation between protein expression of FOXJ1 and the 5-year survival rate of patients with tubo-ovarian high-grade serous carcinoma (HGSC). However, protein expression of GMNN was not significantly associated with patient survival. This study provides preliminary evidence for the prognostic value of FOXJ1 in HGSC and validates the prior mRNA-based prognostic association through immunohistochemistry.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
C. Mueller, V Kiver, E-F Solomayer, G. Wagenpfeil, C. Neeb, J. U. Blohmer, A. Abramian, N. Maass, F. Schuetz, C. Kolberg-Liedtke, D. J. Ralser, A-C Rambow
Summary: This study presents real-world data on the treatment of HR+/HER2- ABC patients with CDK4/6 inhibitors in four certified German university breast cancer centers. The results support the efficacy and safety of CDK4/6 inhibitors as shown in randomized controlled trials (RCTs). However, the median progression-free survival (PFS) in real-world data was lower than that in RCTs, which may be due to the inclusion of patients with more advanced disease.
Article
Oncology
Eun-Young Kang, Ashley Weir, Nicola S. Meagher, Kyo Farrington, Gregg S. Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J. Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S. Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W. Beckmann, Jessica Berger, Christiani Bisinotto, Hans Boesmueller, Jessica Boros, Alison H. Brand, Angela Brooks-Wilson, Sara Y. Brucker, Michael E. Carney, Yovanni Casablanca, Alicia Cazorla-Jimenez, Paul A. Cohen, Thomas P. Conrads, Linda S. Cook, Penny Coulson, Madeleine Courtney-Brooks, Daniel W. Cramer, Philip Crowe, Julie M. Cunningham, Cezary Cybulski, Kathleen M. Darcy, Mona A. El-Bahrawy, Esther Elishaev, Ramona Erber, Rhonda Farrell, Sian Fereday, Anna Fischer, Maria J. Garcia, Simon A. Gayther, Aleksandra Gentry-Maharaj, C. Blake Gilks, Marcel Grube, Paul R. Harnett, Shariska Petersen Harrington, Philipp Harter, Arndt Hartmann, Jonathan L. Hecht, Sebastian Heikaus, Alexander Hein, Florian Heitz, Joy Hendley, Brenda Y. Hernandez, Susanna Hernando Polo, Sabine Heublein, Akira Hirasawa, Estrid Hogdall, Claus K. Hogdall, Hugo M. Horlings, David G. Huntsman, Tomasz Huzarski, Andrea Jewell, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Dineo Khabele, Felix K. F. Kommoss, Roy F. P. M. Kruitwagen, Diether Lambrechts, Nhu D. Le, Marcin Lener, Jenny Lester, Yee Leung, Anna Linder, Liselore Loverix, Jan Lubinski, Rashna Madan, G. Larry Maxwell, Francesmary Modugno, Susan L. Neuhausen, Alexander Olawaiye, Siel Olbrecht, Sandra Orsulic, Jose Palacios, Celeste Leigh Pearce, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Cristina Rodriguez-Antona, Matthias Ruebner, Andy Ryan, Stuart G. Salfinger, Naoko Sasamoto, Joellen M. Schildkraut, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Yurii B. Shvetsov, Naveena Singh, Gabe S. Sonke, Linda Steele, Colin J. R. Stewart, Karin Sundfeldt, Anthony J. Swerdlow, Aline Talhouk, Adeline Tan, Sarah E. Taylor, Kathryn L. Terry, Aleksandra Toloczko, Nadia Traficante, Koen K. Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian Van-Wagensveld, Ignace Vergote, Robert A. Vierkant, Chen Wang, Lynne R. Wilkens, Stacey J. Winham, Anna H. Wu, Javier Benitez, Andrew Berchuck, Francisco J. Candido Dos Reis, Anna DeFazio, Peter A. Fasching, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Beth Y. Karlan, Stefan Kommoss, Usha Menon, Hans-Peter Sinn, Annette Staebler, James D. Brenton, David D. Bowtell, Paul D. P. Pharoah, Susan J. Ramus, Martin Kobel
Summary: This study validates that high-level amplification of CCNE1 is associated with shorter survival in tubo-ovarian high-grade serous carcinoma (HGSC), supporting its use as a prognostic biomarker in this disease.
Article
Pathology
Felix K. F. Kommoss, Lisa-Marie Mar, Brooke E. Howitt, Krisztina Hanley, Gulisa Turashvilli, Rolf Buslei, Julie A. Irving, Brendan C. Dickson, Christian Koelsche, Hans-Peter Sinn, Peter Schirmacher, Andreas von Deimling, Sarah Chiang, W. Glenn McCluggage, Sabrina Croce, Colin J. R. Stewart, Cheng-Han Lee
Summary: This study molecularly characterized 36 cases of high-grade endometrial stromal sarcoma (HGESS), and found that these tumors frequently harbor recurrent events involving the CDKN2A locus on chromosome 9p. The study showed that CDKN2A alterations are a cooperative driver of tumorigenesis in a subset of HGESSs with the YWHAE::NUTM2 gene fusion, and that p16 may be a potential prognostic marker.
Article
Oncology
Benedikt Schafgen, Annabelle Haller, Hans-Peter Sinn, Manuel Feisst, Christina Gomez, Anne Stieber, Juliane Nees, Riku Togawa, Andre Pfob, Andre Hennigs, Johanna Hederer, Fabian Riedel, Sarah Fastner, Joerg Heil, Michael Golatta
Summary: This study aimed to evaluate the accuracy of intraoperative specimen radiography (CSR) in diagnosing breast cancer and reducing second surgeries. The results showed that CSR had low effectiveness in patients treated with neoadjuvant chemotherapy, questioning its routine use and suggesting the need for alternative intraoperative margin assessment tools.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Marc Thill, Cornelia Kolberg-Liedtke, Ute-Susann Albert, Maggie Banys-Paluchowski, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A. Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Hartkopf, Joerg Heil, Jens Huober, Christian Jackisch, Hans-Heinrich Kreipe, David Krug, Thorsten Kuehn, Sherko Kuemmel, Sibylle Loibl, Diana Lueftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schuetz, Hans Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Isabell Witzel, Achim Woeckel, Volkmar Mueller, Rachel Wuerstlein, Wolfgang Janni, Tjoung-Won Park-Simon
Summary: The Breast Committee of the German Gynecological Oncology Group (AGO) has released the 2023 update on evidence-based recommendations for diagnosing and treating patients with locally advanced and metastatic breast cancer (mBC).
Article
Oncology
Tjoung-Won Park-Simon, Volkmar Mueller, Christian Jackisch, Ute-Susann Albert, Maggie Banys-Paluchowski, Ingo Bauerfeind, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A. Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas D. Hartkopf, Joerg Heil, Jens Huober, Cornelia Kolberg-Liedtke, Hans H. Kreipe, David Krug, Thorsten Kuehn, Sherko Kuemmel, Sibylle Loibl, Diana Lueftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schuetz, Hans Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Isabell Witzel, Achim Woeckel, Rachel Wuerstlein, Wolfgang Janni, Marc Thill
Summary: The updated evidence-based treatment recommendations for early and metastatic breast cancer were released in March 2023 by the German Gynecological Oncology Group. This paper provides a concise summary of the updated recommendations for early breast cancer chapter by chapter.
Article
Oncology
Peter A. Fasching, Christopher Szeto, Carsten Denkert, Stephen Benz, Karsten Weber, Patricia Spilman, Jan Budczies, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Christian Jackisch, Thomas Karn, Hans Peter Sinn, Mathias Warm, Marion van Mackelenbergh, Shahrooz Rabizadeh, Christian Schem, Ernst Heinmoller, Volkmar Mueller, Frederik Marme, Patrick Soon-Shiong, Valentina Nekljudova, Michae Untch, Sibylle Loibl
Summary: This study aims to explore the role of immune-cell activity in breast cancer tumors in predicting response to neoadjuvant paclitaxel-based therapy and prognosis. The study found that tumors with high immune-cell activity (hot cluster tumors) and relatively higher tumor-infiltrating lymphocytes (TILs) levels were associated with higher rates of pathologic complete response (pCR) and improved survival. It also observed longer disease-free survival and overall survival in patients with hot or warm cluster tumors, particularly in HR-negative tumors, even with lower TIL levels.
CLINICAL CANCER RESEARCH
(2023)
Article
Endocrinology & Metabolism
A. Marshall, K. F. Kommoss, H. Ortmann, M. Kirchner, J. Jauckus, P. Sinn, T. Strowitzki, A. Germeyer
Summary: This study molecularly characterized the gene expression signatures of adenomyosis uteri (FA) and deep infiltrating endometriosis (DIE). The results showed significant differences in RNA expression levels between the two diseases. Genes belonging to the PI3K pathway were highly expressed in DIE, while genes belonging to the RAS pathway were highly expressed in FA.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
(2023)
Article
Multidisciplinary Sciences
Aoife Ward Gahlawat, Tania Witte, Peter Sinn, Sarah Schott
Summary: Ovarian cancer is an aggressive disease with low survival rates. Liquid biopsy markers, specifically cf-miRNAs, show potential as an independent prognostic factor for survival. Upregulation of miR-200c and miR-141 in both plasma and tissues of OC patients correlates with adverse clinical features. cf-miRNAs are more easily obtained and stable in blood, making them a suitable liquid biopsy marker for OC.
SCIENTIFIC REPORTS
(2023)
Article
Pathology
Zsuzsanna Varga, Peter Sinn, Annette Lebeau
Summary: B3 lesions of the breast are a diverse group of lesions with uncertain malignant potential that present histologically distinct alterations. They are typically detected through mammographic calcifications or mass lesions and can include atypical ductal hyperplasia, classic lobular neoplasia, flat epithelial atypia, papillomas, fibroepithelial tumors, and other rare lesions. Immunohistochemical staining is useful in differentiating these lesions and guiding proper classification. The radiological-pathological correlation is crucial for the clinical management of B3 lesions.
Article
Pathology
Christina C. Westhoff, Annette Ramaswamy, Matthias Kalder, Annette Lebeau, Peter Sinn, Carsten Denkert
Summary: Immunohistological examinations are useful for diagnosing breast carcinoma in various clinical situations. This review article summarizes different immunohistological options, including diagnostic, prognostic, and predictive markers. A quantitative, quality-controlled, and validated diagnostic approach is essential, especially when therapeutic decisions are based on immunohistological expression patterns. This article provides a practical summary of important immunohistochemical markers for routine breast cancer diagnosis and differentiation between malignant and benign lesions.
Article
Pathology
Hans-Peter Sinn, Zsuzsanna Varga
Summary: Triple-negative breast cancer (TNBC), accounting for about 10% of breast cancer cases, lacks expression of estrogen and progesterone receptors and overexpression or amplification of HER2. TNBC differs by younger age, association with BRCA1 mutation, and low differentiation from hormone receptor-positive breast cancer. It exhibits considerable heterogeneity both morphologically and molecularly, including different subtypes with variable gene expression patterns. Therefore, it is recommended to critically use the term TNBC considering histopathological tumor differentiation.